Q-omics provides the consensus-scored TMEM80 profile across patient tissues and cancer cell-line models. TMEM80 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMEM80 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TMEM80 RNA expression shows 18,987 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, THCA, and ACC as cancer lineages where TMEM80 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM80 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM80 survival associations across molecular data types. TMEM80 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM80 RNA expression–survival associations across cancer types. High TMEM80 expression shows unfavorable associations in ACC, but favorable associations in MESO, HNSC, PAAD, CESC and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMEM80 RNA expression.
This table summarizes TMEM80 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM80. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM80 shows lower tumor expression in THCA, KICH, HNSC, UCEC and KIRC and higher tumor expression in LIHC. The THCA box plot shows higher TMEM80 RNA expression in normal versus tumor tissue (log2 FC = −1.115, t-test p < 0.001).
This table shows molecular features associated with TMEM80 in patient tissues and cancer cell lines. In patient samples, TMEM80 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM80 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
